NKGen Biotech Korea
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
NKGen Biotech Korea is listed on KOSDAQ and classified under Health Care, Pharmaceuticals. Its market value is US$200.4M. In FY2025 it reported revenue of US$5.9M and an operating loss of US$1.9M.
A written company profile is not available yet; the facts above come from exchange and DART data.
NKGen Biotech Korea in five facts
Where is NKGen Biotech Korea listed and in which sector?
NKGen Biotech Korea (Korean name: 엔케이젠바이오텍코리아) trades under KRX code 182400 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is NKGen Biotech Korea?
Its market capitalisation was US$200.4M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were NKGen Biotech Korea's latest annual revenue and operating profit?
For fiscal year 2025, NKGen Biotech Korea reported revenue of US$5.9M, an operating loss of US$1.9M and a net loss of US$5.5M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 10.7% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Half-year report (2026.06)Sep 30
- [Amended] Share-pledge agreement that may change the largest shareholder
NKGen Biotech Korea's largest shareholder (NKGen Biotech, Inc.) pledged shares as loan collateral, securing up to US$26.4M.
Ownership change · Apr 22 · 2 versions - [Amended] Material event report (rights offering)
NKGen Biotech Korea updated the terms of a private placement (third-party allotment) to raise US$650K, about 0.4% of its market value.
Capital raise · Feb 19 · 2 versions - [Amended] Material event report (rights offering)
NKGen Biotech Korea updated the terms of a private placement (third-party allotment) to raise US$940K, about 0.5% of its market value.
Capital raise · Feb 19 - Securities issuance results (voluntary) (third-party placement)Capital raise · Feb 2
- [Amended] Material event report (rights offering)Capital raise · Jan 22
- [Amended] Material event report (rights offering)Capital raise · Jan 20
- [Amended] Material event report (rights offering)Capital raise · Jan 7